申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2022237719A1
公开(公告)日:2022-11-17
Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows: wherein R1a, R1b, R2, R3, R4, U, Y1, X1, X2, n1, n2, n3 and n4 are defined herein.
本发明涉及组合物,包括治疗有效量的公式(I)的menin-MLL抑制剂或其药学上可接受的盐或溶剂;以及至少一种其他治疗剂量的治疗剂,其是一种低甲基化剂,胞嘧啶脱氨酶抑制剂,DNA内插剂,嘧啶类似物,嘌呤类似物,激酶抑制剂,CD20抑制剂,IDH抑制剂,免疫调节剂或DHODH抑制剂。还公开了使用这些组合物治疗已被诊断为癌症的受试者的方法。化合物的公式(I)如下:其中R1a,R1b,R2,R3,R4,U,Y1,X1,X2,n1,n2,n3和n4在此定义。